#1 out of 6
business1d ago
Amgen CEO says weight loss drug can address 'patient persistence issue'
- Amgen CEO notes weight-loss drug could address patient persistence issues in obesity treatment.
- Company aims to improve real-world effectiveness through enhanced patient onboarding and support.
- Amgen emphasizes durable results and a simpler treatment course to boost adherence.
- CEO statements align with broader push to grow obesity therapy portfolio.
- Amgen signals potential for greater uptake if persistence improves.
- Therapy could influence long-term treatment decisions in obesity care.
- Company discusses onboarding and ongoing support to sustain use.
- Amgen’s focus remains on real-world effectiveness beyond clinical trials.
- Drug's adherence potential could influence market adoption strategy.
- The remarks come as Amgen expands its obesity-focused initiatives.
Vote 0





